According to results from two clinical trials, triple-dose therapy proved promising in patients with COPD.
The trials, called TRILOGY and TRINITY, examined fixed-dose triple therapy with an inhaled steroid, long-acting beta agonist, and long-acting muscarinic antagonist (ICS/LABA/LAMA).
Free-dose triple therapy is recommended and widely used in patients with COPD, but the presentations mark the first time that a triple combination ICS/LABA/LAMA fixed-dose inhaler has been shown to be superior to standard treatment with ICS/LABA or a LAMA alone, according to the presenters at the European Respiratory Society International Congress.
The TRILOGY data also were published in the Lancet.
